However, despite the high overall response rates, long-term follow-up data indicate that CD19-targeted CAR T cells are likely to be curative for only a subset of patients with B cell lymphomas [2,42,43,44]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.